Company news

Rigel Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Rigel Sharpens Focus on Its Advanced Portfolio Opportunities

November 14, 2021

Rigel Reports Third Quarter 2021 Financial Results and Provides Business Update

November 1, 2021

Rigel Pharmaceuticals Provides Update on COVID-19 Program

August 12, 2021

Rigel Reports Second Quarter 2021 Financial Results and Provides Business Update

August 2, 2021

Rigel Announces Conference Call and Webcast to Report Second Quarter 2021 Financial Results and Business Update

July 26, 2021

Rigel Appoints Alison L. Hannah, M.D. to Board of Directors

May 13, 2021

Rigel Reports First Quarter 2021 Financial Results and Provides Business Update

May 4, 2021

Rigel Announces Conference Call and Webcast to Report First Quarter 2021 Financial Results and Business Update

April 27, 2021

Rigel Announces Closing of Strategic Collaboration with Lilly

April 6, 2021

Rigel Announces Completion of Patient Enrollment for NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients

March 10, 2021

Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

March 1, 2021

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2020 Financial Results and Business Update

February 22, 2021

Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients

January 28, 2021

Rigel Announces Two Posters Highlighting TAVALISSE at the 62nd ASH Annual Meeting & Exposition

December 3, 2020

Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia

November 22, 2020

Rigel Finalizes the Study Design of its Ongoing Phase 3 Clinical Trial of Fostamatinib in Warm Autoimmune Hemolytic Anemia

November 16, 2020

Rigel Reports Third Quarter 2020 Financial Results and Provides Business Update

November 4, 2020

Rigel Announces Conference Call and Webcast to Report Third Quarter 2020 Financial Results and Business Update

October 28, 2020

Rigel Announces First Patients Enrolled in NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova

October 8, 2020

Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova

September 16, 2020

Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program

August 3, 2020

Rigel Announces Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Business Update

July 27, 2020

Rigel Announces Investigator-Sponsored Trial of Fostamatinib in Patients with COVID-19 Pneumonia

July 13, 2020

Rigel Announces Availability of TAVLESSE® (Fostamatinib Disodium Hexahydrate) in Europe

July 8, 2020

Rigel to Present Four Posters Highlighting IRAK1/4 Inhibitor at the EULAR 2020 E-Congress

June 2, 2020

Rigel Reports First Quarter 2020 Financial Results and Provides Business Update

May 4, 2020

Rigel Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

April 30, 2020

Rigel Announces Conference Call and Webcast to Report First Quarter 2020 Financial Results and Business Update

April 26, 2020

Rigel Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

February 26, 2020

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End Financial Results

February 19, 2020

Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe

November 14, 2019

Rigel Announces Upcoming Data Presentations at the 61st ASH Annual Meeting & Exposition

November 6, 2019

Rigel Announces Third Quarter 2019 Financial Results

November 4, 2019

Rigel Announces Conference Call and Webcast to Report Third Quarter 2019 Financial Results

October 28, 2019

Rigel Pharmaceuticals Provides Business Update Prior to Investor & Analyst Call

October 22, 2019

Rigel Receives Positive Trend Vote from CHMP for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe

October 17, 2019

Rigel to Host Investor and Analyst Call on October 23, 2019

October 15, 2019

Rigel Secures Credit Facility for Up to $60 Million

October 1, 2019

Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia

September 22, 2019

Rigel Announces Second Quarter 2019 Financial Results and Provides Business Update

August 5, 2019

Rigel Announces Conference Call and Webcast to Report Second Quarter 2019 Financial Results

July 29, 2019

Rigel to Present Two Posters Highlighting Fostamatinib at the 24 Congress of the European Hematology Association (EHA)

June 12, 2019

← Newer news releases

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 15 decks. Every deck is listed under its year.